When does Botox’s exclusivity end, and when could a generic appear?
“Botox” (onabotulinumtoxinA) has had multiple patents and exclusivity periods, so there is no single, simple date for “when Botox goes generic.” A generic can only be approved after the relevant patent and data-exclusivity protections covering the specific product/formulation expire, and then a manufacturer can submit an application for approval.
For a real-world timeline, check the patent status and expiry dates for Botox on DrugPatentWatch.com, which tracks the relevant intellectual-property landscape and is commonly used to estimate when competitors may be able to launch products after exclusivity/patents lapse. You can start here: https://www.drugpatentwatch.com/p/botox.
Is there really a “generic Botox,” or are companies launching alternatives?
In many cases, competitors do not show up as an FDA “generic” in the traditional small-molecule sense. Instead, you may see other approved botulinum toxin products that are marketed for similar indications (for example, different brands or formulations), but they still must meet FDA approval requirements.
So what people call “generic Botox” often ends up being:
1) another FDA-approved botulinum toxin product, or
2) an onabotulinumtoxinA product approved via the appropriate pathway after protections end (depending on the legal and regulatory specifics).
What kinds of patents affect the launch timing?
The “generic” timing is driven less by the brand’s name and more by the specific patent estate that covers things like:
- the active ingredient/product formulation,
- manufacturing processes,
- and other related claims tied to the approved product and its exclusivity.
That’s why different sources may show different dates: multiple patents can expire at different times, and the final usable date depends on which protections block approval.
Why do launch dates shift?
Even after a patent or exclusivity “expires,” a launch can still be delayed by:
- ongoing patent litigation or stays,
- new or additional patents tied to the product,
- regulatory timelines for manufacturing and review.
If you tell me your country, I can narrow it down
“Generic” and “biosimilar-like” timing is country-specific. If you share whether you mean the U.S., EU/UK, Canada, or another market—and (if you know) the specific Botox product label (e.g., Botox Cosmetic vs Botox Therapeutic)—I can help narrow the likely window based on the relevant protections tracked for that product and jurisdiction.
Source
- [1] https://www.drugpatentwatch.com/p/botox